Intratumoral Vegf and FGF1 administration alters tumor growth, vascular density, oxygenation, and expression of MCP-1 and interleukins

Advances in Experimental Medicine and Biology

Volumn 599, Issue , 2008, Pages 109-116

  Okunieff, Paul ^a   Sun, Jianzhong ^a   Fenton, Bruce ^a   Liu, Weimin ^a   Ding, Ivan ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT FIBROBLAST GROWTH FACTOR 1; RECOMBINANT VASCULOTROPIN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER INHIBITION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE RELEASE; DENSITY; FEMALE; FIBROSARCOMA; HYPOXIA; IMMUNOCYTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME;

MURINAE; MUS;

EID: 84934437898     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-71764-7_15     Document Type: Conference Paper

References (33)

1. I. Ding, K. Huang, X. Wang, J. R. Greig, R. W. Miller, and P. Okunieff P, Radioprotection of hematopoietic tissue by fibroblast growth factors in fractionated radiation experiments, Acta. Oncol.36, 337-340 (1997).
2. I. Ding, T. Wu, H. Matsubara, et al, Acidic fibroblast growth factor (FGF1) increases survival and haematopoietic recovery in total body irradiated C3H/HeNCr mice, Cytokine 9, 59-65 (1997).
3. Z. Fuks, R. S. Persaud, A. Alfieri, et al, Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo, Cancer Res. 54, 2582-2590 (1994).
4. P. Okunieff, M. Mester, J. Wang, et al, In vivo radioprotective effects of angiogenic growth factors on the small bowel of C3H mice, Radiat. Res. 150, 204-211 (1998).
5. X. Wang, I. Ding, H. Xie H, et al, Hyperbaric oxygen and basic fibroblast growth factor promote growth of irradiated bone, Int. J. Radiat. Oncol. Biol. Phys. 40, 189-196 (1998).
6. P. G. Tee , E. L. Travis, Basic fibroblast growth factor does not protect against classical radiation pneumonitis in two strains of mice, Cancer Res. 55, 298-302 (1995).
7. M. Presta, D. B. Rifkin, New aspects of blood vessel growth: tumor and tissue-derived angiogenesis factors, Haemostasis 18, 6-17 (1988).
8. L. Zhang, S. Kharbanda, D. Chen, et al, MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice, Oncogene 15, 2093- 2108 (1997).
9. S. W. McLeskey, J. Kurebayashi, S. F. Honig, et al, Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice, Cancer Res. 53, 2168-2177 (1993).
10. R. Neta, Modulation of radiation damage by cytokines, Stem Cells 15 (Suppl 2), 87-94 (1997).
11. R. Neta, Modulation with cytokines of radiation injury: suggested mechanisms of action, Environ. Health Perspect. 105(Suppl 6), 1463-1465 (1997).
12. J. Folkman, Angiogenesis: initiation and control, Ann. N. Y. Acad. Sci. 401, 212-227 (1982).
13. F. G. Kern, M. E. Lippman, S. W. McLeskey, et al, The role of angiogenic growth factors in breast cancer progression, Cancer Metastas. Rev. 15, 213-219 (1996).
14. B. M. Fenton, S. F. Paoni, J. Lee, C. J. Koch, E. M. Lord, Quantification of tumour vasculature and hypoxia by immunohistochemical staining and HbO2 saturation measurements, Br. J. Cancer 79, 464-471 (1999).
15. B. Bodey, B. Bodey Jr., S. E. Siegel, H. E. Kaiser, Immunocytochemical detection of endoglin is indicative of angiogenesis in malignant melanoma, Anticancer Res. 18, 2701-2710 (1998).
16. B. Bodey, B. Bodey Jr., S. E. Siegel, H. E. Kaiser, Over-expression of endoglin (CD105): a marker of breast carcinoma- induced neo-vascularization, Anticancer Res. 18, 3621-3628 (1998).
17. E. M. Lord, L. Harwell, C. J. Koch, Detection of hypoxic cells by monoclonal antibody recognizing 2- nitroimidazole adducts, Cancer Res. 53, 5721-5726 (1993).
18. A. M. Manning, F. P. Bell, C. L. Rosenbloom, et al, NF-kappa B is activated during acute inflammation in vivo in association with elevated endothelial cell adhesion molecule gene expression and leukocyte recruitment, J. Inflamm. 45, 283-296 (1995).
19. G. Molema, D. K. Meijer, L. F. de Leij, Tumor vasculature targeted therapies: getting the players organized, Biochem. Pharmacol. 55, 1939-1945 (1998).
20. P. Okunieff, X. Wang, M. Li M, et al, Chronic radiation bone toxicity is associated with decreased perfusion without elevation of circulating or soft tissue TGF beta or TNF alpha, Adv. Exp. Med. Biol. 454, 325-333 (1998).
21. P. Okunieff, E. H. Abraham, M. Moini, et al, Basic fibroblast growth factor radioprotects bone marrow and not RIF1 tumor, Acta. Oncol. 34, 435-438 (1995).
22. F. G. Kern, S. W. McLeskey, L. Zhang, et al, Transfected MCF-7 cells as a model for breast-cancer progression, Breast Cancer Res. Treat. 31, 153-165 (1994).
23. J. Yoneda, H. Kuniyasu, M. A. Crispens, J. E. Price, C. D. Bucana, I. J. Fidler, Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice, J. Natl. Cancer Inst. 90, 447-454 (1998).
24. J. T. Leith, S. Michelson, Effects of administration of basic fibroblast growth factor on hypoxic fractions in xenografted DLD-2 human tumours: time dependence, Br. J. Cancer 68, 727-731 (1993).
25. J. T. Leith, G. Papa, L. Quaranto, S. Michelson, Modification of the volumetric growth responses and steady-state hypoxic fractions of xenografted DLD-2 human colon carcinomas by administration of basic fibroblast growth factor or suramin, Br. J. Cancer 66, 345-348 (1992).
26. J. T. Leith, G. Padfield, S. Michelson, Effects of partial hepatectomy on the growth characteristics and hypoxic fractions of xenografted DLD-2 human colon cancers, Radiat. Res. 132, 263-268 (1992).
27. J. T. Leith, P. Harrigan, G. Padfield, L. Faulkner, S. Michelson, Modification of the growth rates and hypoxic fractions of xenografted A431 tumors by sialoadenectomy or exogenously supplied epidermal growth factor, Cancer Res. 51, 4111-4113 (1991).
28. J. T. Leith, Modification of the hypoxic fraction of a xenografted human colon tumor by differentiationinducing agents, J. Natl. Cancer Inst. 80, 444-447 (1988).
29. A. Balsari, J. A. Maier, M. I. Colnaghi, S. Menard, Correlation between tumor vascularity, vascular endothelial growth factor production by tumor cells, serum vascular endothelial growth factor levels, and serum angiogenic activity in patients with breast carcinoma, Lab. Invest. 79, 897-902 (1999).
30. D. Strohmeyer, Pathophysiology of tumor angiogenesis and its relevance in renal cell cancer, Anticancer Res. 19, 1557-1561 (1999).
31. F. Kaplan, J. Sawyer, S. Connors, K. Keough, E. Shore, F. Gannon, D. Glaser, D. Rocke, M. Zasloff, J. Folkman, Urinary basic fibroblast growth factor. A biochemical marker for preosseous fibroproliferative lesions in patients with fibrodysplasia ossificans progressiva, Clin. Orthop. 346, 59-65 (1998).
32. P. Vaupel, D. K. Kelleher, M. Höckel, Oygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy, Semin. Oncol. 28(2 Suppl 8), 29-35 (2001).
33. D. M. Brizel, S. P. Scully, J. M. Harrelson, L. J. Layfield, J. M. Bean, L. R. Prosnitz, M. W. Dewhirst, Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma, Cancer Res. 56(5), 941-943 (1996).